TriSalus Life Sciences Inc.

NASDAQ:TLSI USA Medical Devices
Market Cap
$200.86 Million
Market Cap Rank
#15952 Global
#6193 in USA
Share Price
$4.02
Change (1 day)
-2.43%
52-Week Range
$3.57 - $7.50
All Time High
$11.51
About

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more

TriSalus Life Sciences Inc. - Asset Resilience Ratio

Latest as of March 2022: 24.20%

TriSalus Life Sciences Inc. (TLSI) has an Asset Resilience Ratio of 24.20% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$60.60 Million
Cash + Short-term Investments
Total Assets
$250.40 Million
All company assets
Resilience Assessment
Good
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how TriSalus Life Sciences Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down TriSalus Life Sciences Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $60.60 Million 24.2%
Total Liquid Assets $60.60 Million 24.20%

Asset Resilience Insights

  • Good Liquidity Position: TriSalus Life Sciences Inc. maintains a healthy 24.20% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

TriSalus Life Sciences Inc. Industry Peers by Asset Resilience Ratio

Compare TriSalus Life Sciences Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
Medical Devices 0.01%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.26%
Double Medical Technology Inc
SHE:002901
Medical Devices 7.79%
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
Medical Devices 6.64%
Shinhung
KO:004080
Medical Devices 4.17%
UMediC Group Berhad
KLSE:0256
Medical Devices 1.48%
Osang Healthcare Co.,Ltd
KQ:036220
Medical Devices 9.34%
HansBiomed Corporation
KQ:042520
Medical Devices 9.13%

Annual Asset Resilience Ratio for TriSalus Life Sciences Inc. (None–None)

The table below shows the annual Asset Resilience Ratio data for TriSalus Life Sciences Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points